


## Glucosamine sulfate

<b>Cat. No.:</b>	HY-N0487
<b>CAS No.:</b>	29031-19-4
<b>Molecular Formula:</b>	C <sub>6</sub> H <sub>15</sub> NO <sub>9</sub> S
<b>Molecular Weight:</b>	277.25
<b>Target:</b>	HIF/HIF Prolyl-Hydroxylase; Endogenous Metabolite; Reactive Oxygen Species; Autophagy
<b>Pathway:</b>	Metabolic Enzyme/Protease; Immunology/Inflammation; NF-κB; Autophagy
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : 125 mg/mL (450.86 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	3.6069 mL	18.0343 mL	36.0685 mL
		5 mM	0.7214 mL	3.6069 mL	7.2137 mL
	10 mM	0.3607 mL	1.8034 mL	3.6069 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (360.69 mM); Clear solution; Need ultrasonic				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Glucosamine sulfate (D-Glucosamine sulfate) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a dietary supplement. Glucosamine sulfate also is a natural constituent of glycosaminoglycans in the cartilage matrix and synovial fluid, which when administered exogenously, exerts pharmacological effects on osteoarthritic cartilage and chondrocytes <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Human Endogenous Metabolite
<b>In Vitro</b>	Glucosamine sulfate (D-Glucosamine sulfate) exhibits dose-dependent DPPH antioxidant activity <sup>[2]</sup> . Glucosamine sulfate treatment of Short-term (4 h) inhibits HIF-1α at the protein level, decreases phosphorylation of p70S6K and S6, translation-related proteins <sup>[3]</sup> . Glucosamine sulfate significantly decreases renal expression of α-smooth muscle actin, collagen I, and fibronectin in the obstructed kidneys and TGF-β1-treated renal cells <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- Microbiome. 2019 Mar 20;7(1):43.
- Theranostics. 2021 Mar 24;11(12):5650-5674.
- Laurea Magistrale in Biomedical Engineering, Politecnico di Milano. 2019 Jun.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Bruyère O, et al. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. *Semin Arthritis Rheum.* 2016 Feb;45(4 Suppl):S12-7.
- [2]. Jamialahmadi K, et al. Protective effects of glucosamine hydrochloride against free radical-induced erythrocytes damage. *Environ Toxicol Pharmacol.* 2014 Jul;38(1):212-9.
- [3]. Jo JR, et al. Short-term treatment with glucosamine hydrochloride specifically downregulates hypoxia-inducible factor-1 $\alpha$  at the protein level in YD-8 human tongue cancer cells. *Int J Oncol.* 2014 May;44(5):1699-706.
- [4]. Park J, et al. Glucosamine hydrochloride exerts a protective effect against unilateral ureteral obstruction-induced renal fibrosis by attenuating TGF- $\beta$  signaling. *J Mol Med (Berl).* 2013 Nov;91(11):1273-84.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA